Comparing ImmunityBio (IBRX) & The Competition

ImmunityBio (NASDAQ:IBRXGet Free Report) is one of 290 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it contrast to its competitors? We will compare ImmunityBio to similar businesses based on the strength of its analyst recommendations, risk, valuation, profitability, institutional ownership, dividends and earnings.

Profitability

This table compares ImmunityBio and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ImmunityBio -93,761.41% N/A -114.56%
ImmunityBio Competitors -4,087.08% -222.96% -45.00%

Valuation and Earnings

This table compares ImmunityBio and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
ImmunityBio $620,000.00 -$583.20 million -4.63
ImmunityBio Competitors $558.86 million -$34.30 million 7.10

ImmunityBio’s competitors have higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ImmunityBio and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio 0 1 0 0 2.00
ImmunityBio Competitors 1459 4640 12000 204 2.60

ImmunityBio currently has a consensus price target of $5.00, indicating a potential downside of 6.89%. As a group, “Biological products, except diagnostic” companies have a potential upside of 101.47%. Given ImmunityBio’s competitors stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio has less favorable growth aspects than its competitors.

Risk and Volatility

ImmunityBio has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, ImmunityBio’s competitors have a beta of 1.05, indicating that their average share price is 5% more volatile than the S&P 500.

Institutional and Insider Ownership

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 50.6% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 83.4% of ImmunityBio shares are held by company insiders. Comparatively, 16.3% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

ImmunityBio competitors beat ImmunityBio on 10 of the 13 factors compared.

ImmunityBio Company Profile

(Get Free Report)

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease. The company also develops other therapeutic agents for the treatment of liquid and solid tumors, including bladder, lung, colorectal, and ovarian cancers, as well as glioblastoma multiforme, acute myeloid leukemia, and human immunodeficiency virus. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., and Viracta Therapeutics, Inc. The company is based in San Diego, California.

Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.